{"id":745316,"date":"2016-10-19T06:00:00","date_gmt":"2016-10-19T06:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\/"},"modified":"2025-11-07T01:25:36","modified_gmt":"2025-11-07T06:25:36","slug":"merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\/","title":{"rendered":"Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint"},"content":{"rendered":"<p>\n      Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States<br \/>\n      and Canada, today announced that the pivotal Phase 3 clinical study of<br \/>\n      letermovir, an investigational antiviral medicine, met its primary<br \/>\n      endpoint. The global, multicenter, randomized, placebo-controlled study<br \/>\n      evaluated the efficacy and safety of letermovir for the prevention of<br \/>\n      clinically-significant cytomegalovirus (CMV) infection in adult (18<br \/>\n      years and older) CMV-seropositive recipients of an allogeneic<br \/>\n      hematopoietic stem cell transplant (HSCT). Merck will submit results<br \/>\n      from the study for presentation at a future scientific conference.\n    <\/p>\n<p>\n      \u201cThere is an unmet need for therapeutic options in the prevention of CMV<br \/>\n      infection in high-risk allogeneic hematopoietic stem cell transplant<br \/>\n      recipients,\u201d said Dr. Roy Baynes, senior vice president of clinical<br \/>\n      development, Merck Research Laboratories. \u201cMerck is pleased this pivotal<br \/>\n      Phase 3 study with letermovir met its primary endpoint. We thank the<br \/>\n      patients and families who participated in this study and we look forward<br \/>\n      to presenting results at a future scientific meeting.\u201d\n    <\/p>\n<p>\n      In the study, letermovir was administered once daily, either in oral<br \/>\n      tablet or IV formulation. Letermovir was started as early as the day of<br \/>\n      HSCT transplant and no later than 28 days post-transplant, and continued<br \/>\n      through approximately 100 days after transplant. The primary outcome<br \/>\n      measure was the percentage of participants with clinically-significant<br \/>\n      CMV infection through 24 weeks after transplant. Additional details<br \/>\n      about the study can be found online at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02137772&amp;esheet=51440978&amp;newsitemid=20161019005123&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02137772&amp;index=1&amp;md5=2e7107bb6c8b8c63e2e70cee955d4705\" rel=\"nofollow\">www.clinicaltrials.gov\/ct2\/show\/NCT02137772<\/a>.\n    <\/p>\n<p>\n      <b>About letermovir<\/b>\n    <\/p>\n<p>\n      Letermovir is an investigational once-daily antiviral medicine under<br \/>\n      development for the prevention of CMV infection and disease. It is a<br \/>\n      member of a new class of non-nucleoside CMV inhibitors (3,4<br \/>\n      dihydro-quinazolines) and inhibits viral replication by targeting the<br \/>\n      viral terminase complex. Letermovir has been granted orphan designation<br \/>\n      by the European Medicines Agency, the U.S. Food and Drug Administration<br \/>\n      (FDA) and the Japanese Ministry of Health, Labour and Welfare for the<br \/>\n      prevention of CMV infection and disease in at-risk populations.<br \/>\n      Letermovir also has been granted Fast Track designation by the FDA.\n    <\/p>\n<p>\n      Under an agreement signed in 2012, Merck (through a subsidiary)<br \/>\n      purchased worldwide rights to develop and commercialize letermovir from<br \/>\n      AiCuris GmbH &amp; Co KG (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aicuris.com&amp;esheet=51440978&amp;newsitemid=20161019005123&amp;lan=en-US&amp;anchor=www.aicuris.com&amp;index=2&amp;md5=8b923fd7f5a4e8af54be52b8b57adb3a\" rel=\"nofollow\">www.aicuris.com<\/a>).\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51440978&amp;newsitemid=20161019005123&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=92a91f29e93fa521a3bc2e545e777903\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51440978&amp;newsitemid=20161019005123&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=04423c361c0eb60dde5e2bbb972ede64\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51440978&amp;newsitemid=20161019005123&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=7f6c9b619e60e28a35b92ecbcb046c54\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51440978&amp;newsitemid=20161019005123&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=092a180a728aed4e28211ee43e773e42\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51440978&amp;newsitemid=20161019005123&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=490d8946824bfa7999f40abf26964853\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51440978&amp;newsitemid=20161019005123&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=ad4deb5aab7c8ae94f869d10e2b81f46\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20161019005123r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>Robert Consalvo,        908-236-1127<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint. The global, multicenter, randomized, placebo-controlled study evaluated the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). Merck will submit results from the study for presentation at a future scientific conference. \u201cThere is an unmet need for therapeutic options in the prevention of CMV infection in high-risk allogeneic hematopoietic stem cell transplant recipients,\u201d said Dr. Roy Baynes, senior vice president of clinical development, Merck Research Laboratories. \u201cMerck is pleased this pivotal Phase 3 study with letermovir met its primary endpoint. We thank the patients and families who<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745316","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint. The global, multicenter, randomized, placebo-controlled study evaluated the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). Merck will submit results from the study for presentation at a future scientific conference. \u201cThere is an unmet need for therapeutic options in the prevention of CMV infection in high-risk allogeneic hematopoietic stem cell transplant recipients,\u201d said Dr. Roy Baynes, senior vice president of clinical development, Merck Research Laboratories. \u201cMerck is pleased this pivotal Phase 3 study with letermovir met its primary endpoint. We thank the patients and families who\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\\\/\",\"name\":\"Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-10-19T06:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint - Merck.com","og_description":"Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint. The global, multicenter, randomized, placebo-controlled study evaluated the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). Merck will submit results from the study for presentation at a future scientific conference. \u201cThere is an unmet need for therapeutic options in the prevention of CMV infection in high-risk allogeneic hematopoietic stem cell transplant recipients,\u201d said Dr. Roy Baynes, senior vice president of clinical development, Merck Research Laboratories. \u201cMerck is pleased this pivotal Phase 3 study with letermovir met its primary endpoint. We thank the patients and families who","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:36+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\/","name":"Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-10-19T06:00:00+00:00","dateModified":"2025-11-07T06:25:36+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-pivotal-phase-3-study-of-letermovir-an-investigational-antiviral-medicine-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients-met-primary-e\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"9614f4e7-714b-4811-a324-ea42d49e02bb","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745316\/revisions"}],"predecessor-version":[{"id":3674723,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745316\/revisions\/3674723"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745316"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}